MARKET

MRNA

MRNA

Moderna
NASDAQ
49.04
-0.99
-1.98%
After Hours: 48.98 -0.06 -0.12% 19:58 05/15 EDT
OPEN
48.43
PREV CLOSE
50.03
HIGH
49.88
LOW
47.91
VOLUME
7.23M
TURNOVER
--
52 WEEK HIGH
59.55
52 WEEK LOW
22.28
MARKET CAP
19.46B
P/E (TTM)
-6.0200
1D
5D
1M
3M
1Y
5Y
1D
Moderna Stock Stumbles as Vaccine Hype Meets Reality
TipRanks · 1h ago
Assessing Moderna (MRNA) Valuation After Flu Vaccine Data And Hantavirus Program Interest
Simply Wall St · 5h ago
Coatue adds ASML, exits Chagee, boosts NuBank stake, among Q1 trades
Seeking Alpha · 17h ago
Davis to become acting director of CDER after Hoeg exit, Bloomberg says
TipRanks · 19h ago
FDA leadership fallout continues as acting CDER Director Hoeg expected to depart
Seeking Alpha · 21h ago
Moderna and Merck Push Personalized Lung Cancer Vaccine Into Phase 3
TipRanks · 22h ago
Analysts Conflicted on These Healthcare Names: Qiagen (QGEN), SAB Biotherapeutics (SABS) and Moderna (MRNA)
TipRanks · 2d ago
Moderna’s TIME Ranking And Combo Vaccine Approval Reshape Growth Question
Simply Wall St · 2d ago
More
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Webull offers Moderna Inc stock information, including NASDAQ: MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.